BRKR vs DNA
BRKR: Bruker is a global leader in high-performance analytical instrumentation and diagnostic solutions for life sciences and materials research, enabling structural biology, drug discovery, and scientific innovation at molecular levels. DNA: Ginkgo Bioworks engineers biology at scale through lab automation, AI-driven R&D services, and biosecurity infrastructure to help customers develop new therapeutics, vaccines, industrial chemicals, and biological threat detection.
Side-by-side fundamentals
| Metric | BRKR | DNA | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $62.15 | $7.93 | |
| Market cap as of 2026-07-24 | $9.4B | $515M | |
| PEG as of 2026-07-24 | 1.67 | n/a | |
| Net margin as of 2026-07-24 | -0.3% | -215.4% | BRKR higher |
| Gross margin as of 2026-07-24 | +46.7% | +73.1% | DNA higher |
| Operating margin as of 2026-07-24 | +0.8% | -220.9% | BRKR higher |
| ROE as of 2026-07-24 | -0.5% | -57.3% | BRKR higher |
| ROA as of 2026-07-24 | -0.2% | -26.6% | BRKR higher |
| Debt / equity as of 2026-07-24 | 0.68 | 0.00 | DNA lower |
| Revenue growth (YoY) as of 2026-07-24 | +0.4% | -40.5% | BRKR higher |
| Revenue CAGR (3y) SEC XBRL | +10.7% | -29.1% | BRKR higher |
| Dividend yield as of 2026-07-24 | +0.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-24 | 1.26 | 1.76 | |
| 1-year return as of 2026-07-23 close | +55.7% | -41.3% | BRKR higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.